(2S,5S)-1-(Tert-Butoxycarbonyl)-5-Methylpyrrolidine-2-Carboxylic Acid

In the kilogram-scale synthesis of the NS3/4A protease inhibitor voxilaprevir, the (2S,5S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid fragment serves as a proline surrogate whose stereochemistry dictates macrocyclic ring conformation. The Boc-protected amino acid is activated in situ using 1.05 eq of HATU and 2.5 eq of N,N-diisopropylethylamine in anhydrous dimethylformamide at −15 °C ± 3 °C. The resulting active ester is coupled to the des-methyl macrocyclic amine intermediate. Process analytical technology—typically ReactIR equipped with a diamond ATR probe—tracks disappearance of the acid carbonyl stretch at 1748 cm⁻¹ and controls exotherm to prevent epimerization at C-2. After aqueous workup and solvent switch to 2-propanol/water (85:15 v/v), crude voxilaprevir is crystallized by controlled cooling from 50 °C to 5 °C at 0.1 °C/min. Genotoxic impurity control for residual HATU-derived tetramethylurea requires LC-MS/MS monitoring with a reporting threshold of 1.5 ppm. Final drug substance must meet EP monograph specifications for voxilaprevir: chiral purity ≥ 99.8 area% by SFC on a Chiralpak AD-H column, and ≤ 720 ppm residual DMF per ICH Q3C Option 1. Equipment train typically involves a 200 L glass-lined reactor, Hastelloy C-22 filter-dryer, and vacuum tray oven capable of maintaining ≤ −0.095 MPa gauge pressure and 40 °C jacket temperature for 18 h drying cycles.

Elimination of β-Hydride Shift Byproducts in Voxilaprevir Macrocyclization

When the Boc-5-methylproline fragment is incorporated at large scale, a competing β-hydride elimination in the coupling step can generate a des-methyl pyrroline impurity that co-elutes with the product on reversed-phase HPLC. Suppression of this impurity requires strict anhydrous conditions (water content ≤ 0.03 % by Karl Fischer titration in the activation solvent), and addition of 0.2 eq LiCl to the coupling mixture. The lithium cation coordinates the amide carbonyls during ring closure, elevating the activation barrier for elimination. Process validation batches demonstrate that with LiCl doping, the β-hydride byproduct remains below 0.10 area% in isolated product. Downstream, high-resolution mass spectrometry with electrospray ionization (ESI-HRMS) on a Q-TOF instrument (resolution ≥ 40,000 FWHM) is used for batch release, with characterization to m/z 0.5 ppm mass accuracy. Compliance with ICH M7 on mutagenic impurities is documented through a dedicated PUR structure based on Ames test results for the Boc-hydrated derivative.

Manufacture of Glecaprevir employs the same (2S,5S)-Boc-5-methylproline building block in a convergent route that assembles the macrocycle via an intermolecular amide bond and subsequent ring-closing metathesis. Here, the Boc-protected proline acid is not activated as the HATU ester; instead, it is first converted to a mixed carbonic anhydride using isobutyl chloroformate (1.03 eq) and N-methylmorpholine (1.10 eq) in tetrahydrofuran at −20 °C under nitrogen. The mixed anhydride solution is filtered through a 0.2 μm inline membrane to reject N-methylmorpholinium chloride precipitate before addition to the amino core. Reaction completion is confirmed by TLC (silica gel 60 F₂₅₄, ethyl acetate/n-heptane 1:1) with UV visualization at 254 nm. After acidic quench ( 10 % w/w citric acid), the organic phase is washed with 5 % w/w sodium bicarbonate and brine, dried over anhydrous sodium sulfate, and concentrated to a foam. The resulting intermediate is telescoped into the RCM step without isolation, reducing cycle time by 40 %. Regulatory starting material justification under ICH Q11 requires that the chiral purity of the incoming Boc-amino acid is ≥ 99.5 ee as determined by derivatisation with Marfey’s reagent and analysis by HPLC on a C18 column using a 0.1 % TFA/acetonitrile gradient.

The free amine, generated by quantitative deprotection of the Boc group with 4.0 M HCl in 1,4-dioxane, is a versatile organocatalyst for enantioselective aldol reactions between ketones and aromatic aldehydes. Unlike unsubstituted proline, the 5-methyl group introduces a sterically constrained pyrrolidine ring that shifts the major transition state from an enamine-intermediate to a different geometry. When (2S,5S)-5-methylpyrrolidine-2-carboxylic acid is loaded at 15 mol% in dimethyl sulfoxide at 25 °C, the addition of acetone to 4-nitrobenzaldehyde proceeds with 92 % conversion after 48 h, an enantiomeric excess of 84 % (R), and a diastereomeric ratio of 95:5 syn/anti as determined by chiral stationary-phase HPLC on a Chiralpak AS-H column. Replacement of DMSO with N-dimethylacetamide reduces reaction time to 24 h while improving selectivity to 88 % ee. Process robustness depends critically on water activity: a water-doping experiment revealed that a water content exceeding 1.5 % v/v in the solvent decreases turnover frequency by 40 % and broadens the ee distribution by 6 percentage points. The catalyst can be recovered by acidic aqueous extraction; however, repeated recycling beyond 5 cycles results in accumulation of aldol condensation byproducts that irreversibly poison the amine site.

What Limits Catalyst Turnover in Asymmetric Aldol Reactions Using 5-Methylproline Derivatives?

Mechanistic probes using deuterium-labelled acetone (acetone-d₆) and in situ ¹⁹F NMR monitoring of a fluorinated aldehyde substrate reveal that the rate-determining step transitions from enamine formation to C–C bond formation at catalyst loadings above 20 mol%. Under these conditions, the enamine intermediate accumulates to detectable levels and the apparent kinetic order in ketone shifts from 1 to 0, indicating saturation of the catalytic cycle at the enamine intermediate. This kinetic behaviour imposes an operational ceiling on space-time yield that cannot be overcome by simply adding more catalyst. On an industrial pilot scale, optimal throughput is achieved using a microreactor with 1.0 mm inner-diameter channel and a residence time of 45 min, maintaining catalyst loading at 10 mol% and ketone concentration at 3.0 M in dry DMAc. The microreactor configuration provides efficient heat removal (heat transfer coefficient ~500 W/m²·K) and suppresses the exotherm peak, which in batch mode can reach 12 °C over setpoint. After reaction, the dilute product stream is passed through a fixed-bed of SCX-2 cation-exchange resin to scavenge the organocatalyst; the eluate is concentrated to an oil. Final purification by wiped-film distillation at 120 °C and 0.1 mbar yields the aldol adduct as a colourless oil with >99 % purity by GC-FID.

Conformational Restriction Motifs in Fmoc-Based Solid-Phase Synthesis

The Fmoc derivative of (2S,5S)-5-methylproline—prepared from the Boc compound by acidic Boc removal followed by reprotection with Fmoc-OSu in aqueous sodium carbonate/acetonitrile—is incorporated into peptidomimetics on Wang, 2-chlorotrityl, or Rink amide resin. Couplings are performed manually in fritted syringes or automated synthesizers using a 3-fold excess of protected amino acid, 3-fold excess of HBTU/HOBt, and 6-fold excess of DIPEA relative to resin substitution. The steric bulk of the 5-methyl group slows coupling kinetics; double coupling with 60 min reaction time per cycle and NMP as solvent is standard. Incomplete incorporation is detected by Kaiser test—failure to deliver a negative test after second coupling necessitates repetition or capping with acetic anhydride/pyridine (1:1 v/v). After final TFA cleavage and precipitation from cold diethyl ether, the crude peptide is analysed by RP-HPLC on a C8 column. The presence of the 5-methyl substituent induces a characteristic trans amide bond geometry confirmed by the Δδ_Cβ-Cγ NMR chemical shift difference of 4.3 ppm, consistent with a type-II′ β-turn when 5-methylproline occupies the i+1 position. Yield of purified peptide after preparative HPLC typically ranges from 28 to 44 %, with the main loss originating from incomplete Fmoc removal step, as the 5-methyl group shields the N-terminus from piperidine attack. A short pre-treatment with 2 % DBU in DMF for 5 min prior to standard 20 % piperidine deprotection improves Fmoc removal to near-quantitative levels without epimerization, verified by racmization assay of the dipeptide standard using Marfey’s analysis.

Chiral phosphoramidite ligands derived from (2S,5S)-5-methylprolinol are employed in rhodium-catalyzed asymmetric hydrogenation of α,β-unsaturated carboxylic acids. The Boc-protected amino acid is reduced with sodium borohydride–iodine in THF to (2S,5S)-5-methylprolinol, then the primary hydroxyl is converted to a phosphoramidite using hexamethylphosphorous triamide. When applied to the hydrogenation of (Z)-α-acetamidocinnamic acid at 0.1 MPa hydrogen pressure and 25 °C using 1 mol% Rh(COD)₂BF₄ and 1.1 mol% ligand in methanol, the catalyst provides (R)-N-acetylphenylalanine with 96 % ee at full conversion in 2 h. The Boc group on the pyrrolidine nitrogen remains intact through the phosphoramidite synthesis, which eliminates the need for matched protecting groups during subsequent catalyst recovery. After hydrogenation, the rhodium-ligand complex is stable to aqueous workup and can be re-used in a biphasic methanol/heptane system for 3 cycles with 2% erosion in ee per reuse. Metal leaching, quantified by ICP-OES with a detection limit of 0.1 ppm rhodium, remains below the 5 ppm specification for pharmaceutical intermediates under EMA Guideline EMEA/CHMP/SWP/4446/2000. Key operational boundary: exposure of the phosphoramidite ligand to trace moisture during storage leads to partial hydrolysis to the H-phosphonate; dried and stored under argon at −20 °C, ligand integrity is maintained for 6 months as verified by ³¹P NMR.

When Weinreb Amide Pre-Activation Enhances Enantiomeric Excess in Ketone Synthesis

Conversion of the Boc-protected 5-methylproline into its Weinreb amide proceeds via isobutyl chloroformate activation in the presence of N,O-dimethylhydroxylamine hydrochloride. The mixed anhydride method requires strict control of the amine base ratio: 2.5 eq of N-methylmorpholine relative to the amino acid, added portion-wise to maintain pH 8.2–8.5 in the biphasic water/THF mixture. Any pH drop below 8.0 results in premature Boc deprotection, detected by a rise in free amine content beyond 0.5 % by LCMS. After quenching and extraction into ethyl acetate, the Weinreb amide is crystallized from n-heptane with 0.5 % ethyl acetate to give a white crystalline solid in 72–78 % yield and ≥99.5 % HPLC purity. Once prepared, the Weinreb amide reacts with Grignard reagents (methylmagnesium bromide, 3.0 eq) in THF at −30 °C to form the corresponding methyl ketone without racemization at the α-carbon. The reaction is quenched with 1.0 M aqueous ammonium chloride and allowed to warm to 0 °C. Spectroscopic monitoring by in situ ReactIR shows disappearance of the amide band at 1665 cm⁻¹ within 30 min. The crude methyl ketone, after solvent removal, is passed through a short pad of silica gel (eluting with 20 % ethyl acetate in hexane) to remove residual tertiary alcohol byproduct. The Boc group remains intact throughout the ketone formation, enabling direct use in subsequent stereoselective additions for synthesis of complex side chains. This sequence is validated in a reported kilogram-scale application for a preclinical kinase inhibitor intermediate; batch records specify −35 °C as the maximum allowable addition temperature—exceeding this limit causes a 15–20% increase in the undesired tert-alcohol impurity, which is difficult to remove without chromatographic resolution.